--- title: "C-SNP Enrollment Guide: Targeting Diabetes, Cardiovascular, and COPD Populations" description: "C-SNP enrollment grew 61% in four years. Here's how to target chronic condition populations for year-round Special Needs Plan enrollment." url: https://unlockedcrm.ai/blog/csnp-enrollment-guide-diabetes-cardiovascular-copd canonical: https://unlockedcrm.ai/blog/csnp-enrollment-guide-diabetes-cardiovascular-copd category: "Medicare" published: 2026-04-10 author: "unLocked CRM Team" source: unLocked CRM — AI CRM for insurance agents --- # C-SNP Enrollment Guide: Targeting Diabetes, Cardiovascular, and COPD Populations Chronic Special Needs Plans allow beneficiaries with qualifying conditions to enroll year-round — no AEP required, no waiting for a life event. C-SNP enrollment grew 61% between 2020 and 2024, making this one of the fastest-growing segments in Medicare Advantage. ## The Three Major C-SNP Categories ### Diabetes C-SNP Diabetes accounts for over 60% of all C-SNP enrollment nationally. Counties with high diabetes prevalence represent the deepest well of year-round enrollment opportunity. Top markets for diabetes C-SNP campaigns include Providence County, RI (score: 90.6), Jefferson County, AL (85.9), and a cluster of North Carolina counties — Pitt (85.2), Forsyth (85.2), and Guilford (85.2). ### Cardiovascular C-SNP Cardiovascular C-SNPs are the second-largest category, targeting beneficiaries with coronary heart disease. Markets with high CHD prevalence and underserved C-SNP supply represent strong product opportunities. Providence County, RI leads cardiovascular markets (91.2), followed by Forsyth County, NC (86.2), and Jefferson County, AL (85.9). North Carolina dominates with 15 of the top 50 counties. ### Respiratory / COPD C-SNP Lung-condition C-SNPs represent less than 5% of total C-SNP enrollment, which leaves significant whitespace in high-burden counties. COPD prevalence is elevated in Appalachian states, the Deep South, and former industrial corridors. ## Why C-SNPs Are Underutilized Despite explosive growth, most agents underutilize C-SNPs for three reasons: 1. **They do not identify eligible beneficiaries.** Chronic conditions are not visible in standard lead lists. Agents need data that includes health burden indicators at the county level. 2. **They do not understand continuous open enrollment.** Unlike most SEPs, C-SNP enrollment has no time limit. As long as the beneficiary has the qualifying condition, they can enroll at any time. 3. **They focus on general MA plans.** C-SNPs require different positioning. The value proposition is not just "better coverage" — it is "coverage designed specifically for your condition." ## Data-Driven C-SNP Targeting The most effective C-SNP campaigns layer multiple dimensions: - **Disease prevalence data** from CDC PLACES identifies counties with elevated chronic condition rates - **Specialist depth** ensures the C-SNP network includes adequate specialists for the target condition - **Drug coverage depth** matters because chronic conditions require ongoing medication management - **SDOH burden** identifies populations facing social determinants that make specialized care even more critical ## How unLocked CRM Supports C-SNP Campaigns unLocked CRM integrates county-level health burden data and flags prospects in high-prevalence areas. The system tags leads by qualifying condition, tracks enrollment eligibility continuously (since there is no window to expire), and surfaces C-SNP plan options that match each beneficiary's specific chronic condition profile. ## Related - https://unlockedcrm.ai/blog/2026-medicare-special-enrollment-periods-complete-guide - https://unlockedcrm.ai/blog/esrd-sep-enrollment-21st-century-cures-act --- Source: [C-SNP Enrollment Guide: Targeting Diabetes, Cardiovascular, and COPD Populations](https://unlockedcrm.ai/blog/csnp-enrollment-guide-diabetes-cardiovascular-copd) — unLocked CRM, the AI CRM built for insurance agents. Citation permitted with attribution and a link to https://unlockedcrm.ai/blog/csnp-enrollment-guide-diabetes-cardiovascular-copd.